Literature DB >> 29969043

First-in-Human Pilot Study of Implantation of a Scaffold-Free Tissue-Engineered Construct Generated From Autologous Synovial Mesenchymal Stem Cells for Repair of Knee Chondral Lesions.

Kazunori Shimomura1, Yukihiko Yasui1, Kota Koizumi1, Ryota Chijimatsu1, David A Hart1, Yasukazu Yonetani1, Wataru Ando1, Takashi Nishii1, Takashi Kanamoto1, Shuji Horibe1, Hideki Yoshikawa1, Norimasa Nakamura1, Morito Sakaue1, Norihiko Sugita1, Yu Moriguchi1.   

Abstract

BACKGROUND: Articular cartilage has limited healing capacity, owing in part to poor vascularity and innervation. Once injured, it cannot be repaired, typically leading to high risk for developing osteoarthritis. Thus, cell-based and/or tissue-engineered approaches have been investigated; however, no approach has yet achieved safety and regenerative repair capacity via a simple implantation procedure.
PURPOSE: To assess the safety and efficacy of using a scaffold-free tissue-engineered construct (TEC) derived from autologous synovial membrane mesenchymal stem cells (MSCs) for effective cartilage repair. STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: Five patients with symptomatic knee chondral lesions (1.5-3.0 cm2) on the medial femoral condyle, lateral femoral condyle, or femoral groove were included. Synovial MSCs were isolated from arthroscopic biopsy specimens and cultured to develop a TEC that matched the lesion size. The TECs were then implanted into chondral defects without fixation and assessed up to 24 months postoperatively. The primary outcome was the safety of the procedure. Secondary outcomes were self-assessed clinical scores, arthroscopy, tissue biopsy, and magnetic resonance image-based estimation of morphologic and compositional quality of the repair tissue.
RESULTS: No adverse events were recorded, and self-assessed clinical scores for pain, symptoms, activities of daily living, sports activity, and quality of life were significantly improved at 24 months after surgery. Secure defect filling was confirmed by second-look arthroscopy and magnetic resonance imaging in all cases. Histology of biopsy specimens indicated repair tissue approaching the composition and structure of hyaline cartilage.
CONCLUSION: Autologous scaffold-free TEC derived from synovial MSCs may be used for regenerative cartilage repair via a sutureless and simple implantation procedure. Registration: 000008266 (UMIN Clinical Trials Registry number).

Entities:  

Keywords:  cartilage repair; clinical study; mesenchymal stem cell; scaffold free; synovium

Mesh:

Year:  2018        PMID: 29969043     DOI: 10.1177/0363546518781825

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  18 in total

Review 1.  Progress in Osteochondral Regeneration with Engineering Strategies.

Authors:  Hui Gao; Qian Pan; Weiqiang Dong; Yongchang Yao
Journal:  Ann Biomed Eng       Date:  2022-08-22       Impact factor: 4.219

2.  Production of Mesenchymal Progenitor Cell-Derived Extracellular Vesicles in Suspension Bioreactors for Use in Articular Cartilage Repair.

Authors:  Jolene Phelps; Catherine Leonard; Sophia Shah; Roman Krawetz; David A Hart; Neil A Duncan; Arindom Sen
Journal:  Stem Cells Transl Med       Date:  2022-03-03       Impact factor: 7.655

Review 3.  Synovium Derived Mesenchymal Stromal Cells (Sy-MSCs): A Promising Therapeutic Paradigm in the Management of Knee Osteoarthritis.

Authors:  Madhan Jeyaraman; Sathish Muthu; Naveen Jeyaraman; Rajni Ranjan; Saurabh Kumar Jha; Prabhu Mishra
Journal:  Indian J Orthop       Date:  2021-06-10       Impact factor: 1.033

4.  Role of lineage-specific matrix in stem cell chondrogenesis.

Authors:  Jingting Li; Karthikeyan Narayanan; Ying Zhang; Ryan C Hill; Fan He; Kirk C Hansen; Ming Pei
Journal:  Biomaterials       Date:  2019-12-16       Impact factor: 12.479

5.  Histological Analysis of Cartilage Defects Repaired with an Autologous Human Stem Cell Construct 48 Weeks Postimplantation Reveals Structural Details Not Detected by T2-Mapping MRI.

Authors:  Kazunori Shimomura; Hidetoshi Hamada; David A Hart; Wataru Ando; Takashi Nishii; Siegfried Trattnig; Stefan Nehrer; Norimasa Nakamura
Journal:  Cartilage       Date:  2021-01-29       Impact factor: 3.117

6.  Human Synovial Mesenchymal Stem Cells Good Manufacturing Practices for Articular Cartilage Regeneration.

Authors:  Tiago Lazzaretti Fernandes; Heitor Akio Kimura; Carla Cristina Gomes Pinheiro; Kazunori Shimomura; Norimasa Nakamura; José Ricardo Ferreira; Andreas H Gomoll; Arnaldo Jose Hernandez; Daniela Franco Bueno
Journal:  Tissue Eng Part C Methods       Date:  2018-12       Impact factor: 3.056

Review 7.  Synovium-Derived Mesenchymal Stem Cell Transplantation in Cartilage Regeneration: A PRISMA Review of in vivo Studies.

Authors:  Kendrick To; Bridget Zhang; Karl Romain; Christopher Mak; Wasim Khan
Journal:  Front Bioeng Biotechnol       Date:  2019-11-15

8.  Divergence in chondrogenic potential between in vitro and in vivo of adipose- and synovial-stem cells from mouse and human.

Authors:  Chijimatsu Ryota; Miwa Satoshi; Okamura Gensuke; Miyahara Junya; Tachibana Naohiro; Ishikura Hisatoshi; Higuchi Junya; Maenohara Yuji; Tsuji Shinsaku; Sameshima Shin; Takagi Kentaro; Nakazato Keiu; Kawaguchi Kohei; Yamagami Ryota; Inui Hiroshi; Taketomi Shuji; Sakae Tanaka; Taku Saito
Journal:  Stem Cell Res Ther       Date:  2021-07-15       Impact factor: 6.832

Review 9.  Synovial membrane mesenchymal stem cells: past life, current situation, and application in bone and joint diseases.

Authors:  Na Li; Jinfang Gao; Liangyu Mi; Gailian Zhang; Liyun Zhang; Na Zhang; Rongxiu Huo; Junping Hu; Ke Xu
Journal:  Stem Cell Res Ther       Date:  2020-09-07       Impact factor: 6.832

10.  Surgical Trends in Articular Cartilage Injuries of the Knee, Analysis of the Truven Health MarketScan Commercial Claims Database from 2005-2014.

Authors:  Nicholas A Bonazza; Dallas M Smuin; Rajat Joshi; Djibril Ba; Guodong Liu; Douglas L Leslie; Aman Dhawan
Journal:  Arthrosc Sports Med Rehabil       Date:  2019-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.